Claims
- 1. A method for treatment of congestive heart failure, angina, occlusive peripheral vascular disease or cerebral vascular disease in mammals, which method comprises administering to the mammal in need of such treatment an effective amount of a compound of formula (I): ##STR4## wherein: either one of R.sub.1 and R.sub.2 is hydrogen and the other is selected from the class consisting of C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbonyloxy, C.sub.1-6 alkylhydroxymethyl, nitro, cyano, chloro, trifluoromethyl, C.sub.1-6 alkylsulphinyl, C.sub.1-6 alkylsulphonyl, C.sub.1-6 alkoxysulphinyl, C.sub.1-6 alkoxysulphonyl, C.sub.1-6 alkylcarbonylamino, C.sub.1-6 alkoxycarbonylamino, C.sub.1-6 alkyl-thiocarbonyl, C.sub.1-6 alkoxy-thiocarbonyl, C.sub.1-6 alkyl-thiocarbonyloxy, C.sub.1-6 alkyl-thiolmethyl, formyl, aminosulphinyl, aminosulphonyl and aminocarbonyl, the amino moiety being unsubstituted or substituted by one or two C.sub.1-6 alkyl groups, or C.sub.1-6 alkylsulphinylamino, C.sub.1-6 alkylsulphonylamino, C.sub.1-6 alkoxysulphinylamino, C.sub.1-6 alkoxysulphonylamino or ethylenyl terminally substituted by C.sub.1-6 alkylcarbonyl, nitro, cyano, --C(C.sub.1-6 alkyl) NOH or --C(C.sub.1-6 alkyl)NNH.sub.2, or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.1-3 alkylcarbonyl and the other is methoxy or amino unsubstituted or substituted by one or two C.sub.1-6 alkyl or by C.sub.2-7 alkanoyl; one of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl or R.sub.3 and R.sub.4 together are C.sub.2-5 polymethylene; R.sub.5 is hydrogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy and R.sub.6 is hydrogen, or R.sub.5 and R.sub.6 together are a bond; R.sub.7 is hydrogen, C.sub.1-6 alkyl being unsubstituted or substituted by hydroxy, C.sub.1-6 alkoxy, C.sub.1-6 alkoxycarbonyl or carboxy, C.sub.1-6 alkyl substituted by halogen, or C.sub.2-6 alkenyl, phenyl, haphthyl or heteroaryl each of which is unsubstituted or substituted by one or two groups or atoms which are C.sub.1-6 alkoxy, hydroxy, halogen, trifluoromethyl, nitro, cyano, C.sub.1-12 carboxylic acyl or amino or aminocarbonyl being unsubstituted or substituted by one or two C.sub.1-6 alkyl groups and wherein the heteroaryl moiety is selected from the list of groups as defined hereinafter; R.sub.8 is hydrogen or C.sub.1-6 alkyl; or R.sub.7 and R.sub.8 are joined together to form C.sub.3-4 polymethylene or --CH.sub.2 --(CH.sub.2).sub.n --Z--(CH.sub.2)m-- where m and n are integers of 0 to 2 such that m+n is 1 or 2 and Z is oxygen, sulphur or NR.sub.9 wherein R.sub.9 is hydrogen, C.sub.1-9 alkyl, C.sub.2-7 alkanoyl, phenyl C.sub.1-4 alkyl, naphthylcarbonyl, phenylcarbonyl or benzylcarbonyl being unsubstituted or substituted in the phenyl or naphthyl ring by one or two C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; heteroaryl carbonyl; and wherein heteroaryl moieties in R.sub.7 and R.sub.9 are selected from the group consisting of furanyl, thiophenyl, pyrryl, oxazolyl, thiazolyl, imidazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, benzothiophenyl, indolyl, indazolyl, quinolinyl, isoquinolinyl and quinazoninyl; X is oxygen or sulphur; and the R.sub.8 NCXR.sub.7 moiety is trans to the R.sub.5 group when R.sub.5 is hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy; or a pharmaceutically acceptable salt or hydrate thereof.
- 2. A method according to claim 1 wherein one of R.sub.1 and R.sub.2 is hydrogen and the other is C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxycarbonyl, nitro or cyano.
- 3. A method according to claim 2 wherein R.sub.1 is cyano and R.sub.2 is hydrogen.
- 4. A method according to claim 1 wherein R.sub.3 and R.sub.4 are both methyl.
- 5. A method according to claim 1 wherein R.sub.5 is hydroxy and R.sub.6 is hydrogen.
- 6. A method according to claim 1 wherein R.sub.7 and R.sub.8 are joined together to form C.sub.3-4 polymethylene.
- 7. A method according to claim 1 wherein R.sub.7 is methyl and R.sub.8 is methyl, ethyl or hydrogen.
- 8. A method according to claim 1 wherein the compound of formula (I) is of formula (II): ##STR5## wherein p is 1 or 2 and the remaining variables are as defined in claim 1.
- 9. A method according to claim 1 wherein the compound of formula (I) is 6-cyano-3,4-dihydro-2,2-dimethyl-trans-4-(2-oxo-1-pyrrolidinyl)-2H-benzo[b]pyran-3-ol.
- 10. A method according to claim 1 wherein the compound of formula (I) is trans-4-N-acetyl-ethylamino-6-cyano-3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3-ol.
- 11. A method according to claim 9 for the treatment of occlusive peripheral vascular disease.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8419516 |
Jul 1984 |
GBX |
|
CROSS-REFERENCE
This is a continuation of Ser. No. 760,826, filed July 31, 1985, now abandoned.
US Referenced Citations (9)
Continuations (1)
|
Number |
Date |
Country |
Parent |
760826 |
Jul 1985 |
|